HALO News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

HA

Mkt Cap

$13.83B

Volume

1.45M

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

5 Stocks to Buy Using the Relative Price Strength StrategyU.S. equities remain resilient despite AI-linked tech weakness, with sector rotation indicating broader market strength. The article recommends a relative price strength strategy to identify stocks outperforming the S&P 500 with solid fundamentals and positive earnings revisions. Five stocks highlighted include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions Holdings, Permian Resources, and Chevron Corporation.Zacks Investment Research · Oct 16, 2026

KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.Zacks Investment Research · Oct 16, 2026

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 GainsDespite the Nasdaq's tech-heavy composition, five non-tech Nasdaq-listed stocks with Zacks Rank #1 ratings are positioned for strong growth. Ross Stores plans 115 store openings with 13% Q2 sales growth, Roku's advertising revenue climbed 24.8%, APA Corp benefits from cost savings and long-term growth projects, Corcept Therapeutics sees strong drug demand with recent FDA approvals, and Halozyme generates royalties from pharma collaborations.Zacks Investment Research · Oct 16, 2026

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth TodayA $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs.Zacks Investment Research · Oct 15, 2026

Top Research Reports for Mastercard, AstraZeneca & SandiskZacks analysts published research on 16 major stocks on October 14, 2026. Mastercard received a Neutral rating despite strong performance, citing competitive pricing pressure and premium valuation concerns. AstraZeneca faces patent erosion challenges but benefits from strong pipeline drugs and expects $80 billion in revenues by 2030. SanDisk received an Outperform rating, driven by AI inference demand and strong datacenter exposure. Other notable stocks analyzed include Exelon, General Mills, and Halozyme, with mixed outlooks across various sectors.Zacks Investment Research · Oct 14, 2026

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)Halozyme Therapeutics is highlighted as an attractive growth stock pick with a Zacks Growth Score of A and Rank #1 (Strong Buy). The company demonstrates exceptional earnings growth of 112.1% projected for the year, significantly outpacing the industry average of 14.7%, along with strong asset utilization efficiency and positive earnings estimate revisions.Zacks Investment Research · Oct 14, 2026

Why Investors Need to Take Advantage of These 2 Medical Stocks NowThe article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies potential earnings surprises by comparing the Most Accurate Estimate to the Zacks Consensus Estimate. Historical data shows that combining a positive ESP with a Zacks Rank #3 or better has resulted in positive earnings surprises 70% of the time, with average annual returns of 28.3%. The article highlights Halozyme Therapeutics and United Therapeutics as examples of stocks with positive ESP figures ahead of their earnings releases.Zacks Investment Research · Oct 14, 2026

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?Halozyme Therapeutics has demonstrated a strong track record of beating earnings estimates, surpassing consensus by an average of 14.59% over the last two quarters. With a positive Earnings ESP of +2.78% and a Zacks Rank #2 (Buy) rating, analysts suggest the company is well-positioned to continue this earnings beat streak in its upcoming quarterly report.Zacks Investment Research · Oct 13, 2026

HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeA Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected.Zacks Investment Research · Oct 8, 2026

HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXHalozyme Therapeutics announced an expansion of its collaboration with argenx, increasing exclusive ENHANZE technology targets from six to eight. The deal includes milestone payments and royalties on product sales. Halozyme raised its 2026 revenue guidance to $1.84-$1.91 billion, driven by strong royalty growth from J&J's Darzalex and argenx's Vyvgart Hytrulo.Zacks Investment Research · Oct 7, 2026

HA

HALOHalozyme Therapeutics, Inc.

HALO

Pay with—

Available Balance0.00

Your PositionYou don't own any HALO yet.

Related Tickers

Earnings